Biodimension raises Rs 8 Cr funding led by IAN Angel Fund
The startup aims to further strengthen its oncology research capabilities, expand its Bioassay-as-a-Service platform.
Bengaluru-based life sciences startup Biodimension has raised Rs 8 crore in a fresh funding round led by IAN Angel Fund.
The round also saw participation from existing investor Campus Angels Network, along with Dr. Sampath Srisailam and angel investor Aaryan Baid.
The newly raised capital will be used to accelerate product development, strengthen laboratory infrastructure, expand scientific and commercial teams, and support the commercialisation of its offerings across domestic and international markets.
Founded in 2021 by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension develops biofabricated human tissue models and organoid-based platforms designed to provide alternatives to traditional animal testing methods.
The startup works with pharmaceutical, biotechnology, and cosmetic companies by providing human-relevant research models that can support drug discovery, toxicity testing, and product evaluation.
Biodimension’s product portfolio includes BioDEpi, BioDFT, BioDPigma, a Pan-Cancer Tumour Microenvironment (TME) Biobank, and its Bioassay-as-a-Service (BaaS) platform.
These solutions are designed to replicate aspects of human biology more accurately, helping researchers improve the efficiency of preclinical studies and develop better insights during the research and development process.
According to the company, Biodimension has established collaborations with pharmaceutical companies, biotechnology firms, research institutions, and contract research organisations across India and Singapore.